Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.61 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12982249 | 0.89 | CYP3A4 (0.58) | CYP3A4SLC7A5NLN | |
| SCHEMBL17697372 | 0.89 | CYP3A4 (0.58) | CYP3A4SLC7A5NLN | |
| SCHEMBL16192880 | 0.88 | CYP3A4 (0.61) | CYP3A4SLC7A5NLN | |
| SCHEMBL21099730 | 0.88 | CYP3A4 (0.57) | CYP3A4SLC7A5NLN | |
| SCHEMBL16377439 | 0.87 | CYP3A4 (0.56) | CYP3A4SLC7A5 | |
| SCHEMBL7602189 | 0.85 | CYP3A4 (0.55) | CYP3A4SLC7A5 | |
| SCHEMBL17922794 | 0.85 | CYP3A4 (0.55) | CYP3A4SLC7A5 | |
| SCHEMBL16363243 | 0.85 | CYP3A4 (0.55) | CYP3A4SLC7A5 | |
| SCHEMBL18878639 | 0.85 | CYP3A4 (0.55) | CYP3A4SLC7A5 | |
| SCHEMBL13331622 | 0.85 | CYP3A4 (0.69) | CYP3A4SLC7A5NLN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | PPM1D, PPM1G, PPM1F | CYP3A4 2191/4885SLC7A5 3768/4885NLN 4862/4885 |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | PPM1F, PPM1D, PPP1R1B | CYP3A4 4184/4885SLC7A5 4451/4885NLN 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.